Scleroderma lung involvement, autoantibodies, and outcome prediction: The confounding effect of time

Journal of Rheumatology

Volumn 44, Issue 4, 2017, Pages 404-406

  Nihtyanova, Svetlana I ^a   Denton, Christopher P ^b  

^a Clinical Research Fellow in Rheumatology   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DNA TOPOISOMERASE; RNA POLYMERASE; RNA POLYMERASE ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY;

DISEASE DURATION; EDITORIAL; FORCED VITAL CAPACITY; HUMAN; LUNG COMPLICATION; LUNG FUNCTION TEST; PREDICTION; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; LOCALIZED SCLERODERMA; PROGNOSIS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; HUMANS; PROGNOSIS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC;

EID: 85016995712     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.170055     Document Type: Editorial

References (19)

1. Komócsi A, Vorobcsuk A, Faludi R, Pintér T, Lenkey Z, Költo G, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology 2012;51:1027-36.
2. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012;51:1017-26.
3. Rubio-Rivas M, Royo C, Simeon CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:208-19.
4. Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010;103:109-15.
5. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nature Rev Rheumatol 2010;6:112-6.
6. Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014;66:1625-35.
7. Motegi S, Toki S, Yamada K, Uchiyama A, Ishikawa O. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies. J Dermatol 2015; 42:189-92.
8. Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011;3:1329-34.
9. Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N. Correlation of delta high-resolution computed tomography (HRCT) score with delta clinical variables in early systemic sclerosis (SSc) patients. Quant Imaging Med Surg 2016;6:381-90.
10. Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 2015;67:3256-61.
11. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177:1248-54.
12. Hoffmann-Vold AM, Midtvedt O, Tennoe AH, Garen T, Lund MB, Aalokken TM, et al. Cardiopulmonary disease development in anti-RNA polymerase III positive systemic sclerosis; comparative analyses from an unselected, prospective patient cohort. J Rheumatol 2017;44:459-65.
13. Foocharoen C, Suwannachat P, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I. Int J Rheum Dis 2016;19:312-20.
14. Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010;40:241-9.
15. Furnari M, Savarino V, de Bortoli N, Savarino E. Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. Autoimmun Rev 2016;15:1208-9.
16. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
17. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437-44.
18. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin N Am 2003;29:255-73, vi.
19. Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007;56:2422-31.